NCT01441037View on ClinicalTrials.gov

Danazol for Genetic Bone Marrow and Lung Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 19, 2011

Primary Completion Date

November 14, 2016

Study Completion Date

November 14, 2016

Conditions
Aplastic Anemia
Interventions
DRUG

Danazol

Danazol, 800 mg daily by mouth for 2 years

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01441037 - Danazol for Genetic Bone Marrow and Lung Disorders | Biotech Hunter | Biotech Hunter